

- Comprehensive women-centered treatment for substance use in Georgia: Initial examination of drug use and HIV risk
- I. Kirtadze¹, D. Otiashvili¹, K. O'Grady², W. Zule³, E. Krupitsky⁴, W. Wechsberg³, H.E. Jones⁵.
¹Addiction Research Center, Alternative Georgia, Georgia; ²Department of Psychology, University of Maryland, United States; ³RTI International, United States; ⁴Department of Addictions, Bekhterev Research Psychoneurological Institute, St. Petersburg, Russia; ⁵University of North Carolina (UNC) Horizons, Department of Obstetrics and Gynecology, UNC at Chapel Hill, United States
521. **Alcohol screening among opioid agonist patients in a primary care and opioid treatment program**
- J. Klimas^{1,2}, J. Muench³, K. Wiest⁴, R. Croff⁵, T. Rieckman⁵, D. McCarty⁵. ¹School of Medicine and Medical Science, University College Dublin, Ireland; ²Addiction & Urban Health Research Initiative, British Columbia Centre for Excellence in HIV/AIDS, Canada; ³Department of Family Medicine, Oregon Health & Science University (OHSU), United States; ⁴Comprehensive Options for Drug Abusers, Inc., United States; ⁵Department of Public Health and Preventive Medicine, OHSU, United States
522. **Anhedonia, depression, anxiety, and craving for opiates in opiate addicts stabilized on oral naltrexone and long-acting naltrexone implant**
- E. Krupitsky^{1,2}, E. Zvartau², E. Blokhina², E. Verbitskaya², V. Palatkin², A. Tyurina², T. Yaroslavtseva¹, N. Bushara², A. Pecoraro³, G. Woody³. ¹St. Petersburg Bekhterev Research Psychoneurological Institute, Russia; ²St. Petersburg Pavlov State Medical University, Russia; ³University of Pennsylvania, United States
523. **Changes of CD4 cell counts in patients with antiretroviral treatment and associated factors, including drug use at outpatient clinics in Hanoi**
- L. La¹, T. Le¹, D. Nguyen¹, H. Nguyen¹, H. Tran¹, D. Cao¹, N. Vu², T. Do², H. Le², X. Le², S. Nguyen³, H. Vu⁴. ¹Hanoi AIDS Center, Vietnam; ²Hanoi School of Public Health, Vietnam; ³Hanoi Medical School, Vietnam; ⁴Substance Abuse and Mental Health Services Administration, U.S. Department of Health and Human Services, Vietnam
524. **Gender differences in drug use patterns as reported by polydrug users seeking treatment in a therapeutic community in Israel (2011–2014)**
- M. Lawental¹, E. Shahar², A. Michael², E. Lawental³. ¹University of Haifa, Israel; ²Ha'Derech TC, Israel; ³Tel-Hai Academic College, Israel
525. **Incremental cost-effectiveness of a voucher-based contingency management protocol added to cognitive behavioral treatment for smoking cessation**
- C. López-Núñez, F. Alonso-Pérez, S. Weidberg, I. Pericot-Valverde, R. Secades-Villa. Department of Psychology, University of Oviedo, Spain
526. **Compulsory addiction treatment and subsequent hospitalizations: A Swedish registry-based study**
- L. Lundgren^{1,2}, D. McCarty³, M. Padyab¹. ¹Umea University, Sweden; ²Boston University, United States; ³Oregon Health & Science University, United States
527. **Implementation of case management to link HIV-infected Russian addiction patients to HIV services**
- K. Lunze¹, T. Kiriazova², E. Blokhina³, N. Gnatienco¹, L. Wulach¹, C. Curnyn¹, N. Bushara³, C. Briden¹, E. Krupitsky³, A. Raj⁴, A. Gifford¹, J.H. Samet¹. ¹Boston University, United States; ²Future Without AIDS, Ukraine; ³First Pavlov State Medical University, Russia; ⁴University of California, San Diego, United States
528. **Effects of cytidine 5'-diphosphocholine administration on gray matter volumes in methamphetamine dependents**
- I.K. Lyoo¹⁻³, S. Yoon¹, Y.H. Sung⁴, J. Hwang⁵, J.E. Kim^{1,3}, E. Namgung^{1,3}, S. Oh^{1,3}, S. Moon^{1,2}, S. Kim^{1,3}, S. Yu^{1,3}, P.F. Renshaw⁴. ¹Ewha Brain Institute, Ewha W. University, South Korea; ²Graduate School of Pharmaceutical Sciences, Ewha W. University, South Korea; ³Brain and Cognitive Sciences, Ewha W. University, South Korea; ⁴The Brain Institute, University of Utah, United States; ⁵Department of Psychiatry, Soonchunhyang University, South Korea
529. **Vocalized truths: Participation of Iranian drug-using women in a qualitative study**
- E. Merghati-Khoei¹, K. Dolan², T. Kileen³, F. Yaddollahi⁴. ¹Iranian National Center of Addiction Studies, Tehran University of Medical Sciences, Iran; ²National Drug and Alcohol Research Centre, University of New South Wales, Australia; ³Clinical Neuroscience Division, Medical University of South Carolina, United States; ⁴School of Public Health, Iran University of Medical Sciences, Iran